EGFR and dermatological toxicity: Patients with mCRC (n = 95) being treated with the EGFR-targeted agent panitumumab and randomly assigned 1:1 to one or other treatment strategy, showed grade ≥2 skin toxicity to be reduced from 62% in the reactive patient group to 29% in the prophylactic patient group during the 6-week skin treatment period (odds ratio 0.3, 95% confidence interval [CI] 0.1–0.6).16 In addition, grade 2 and 3 skin toxicities of interest were reported in 23% and 40% of patients, and 6% and 21% of patients, for the prophylactic and reactive treatment arms, respectively.